BioNTech extends COVID-19 vaccine trial in China to end-Oct
Send a link to a friend
[May 10, 2022]
BEIJING (Reuters) - Vaccine
developer BioNTech has extended by six months to October a Phase II
clinical trial of its COVID-19 vaccine in China, a registry of such
trials showed.
The vaccine, based on messenger RNA (mRNA) technology, is one of the
most widely used worldwide against COVID, but has yet to receive an
approval in China, which has relied only on domestically developed
vaccine.
China's leading medical experts have urged authorities to retain tough
zero-COVID measures so as to buy time and step up vaccination rates and
develop new treatments, in the battle on the country' biggest outbreak.
The Phase II trial on the vaccine's safety and immunogenicity began in
late 2020, targeting completion by the end of April, but this was
extended to the end of October, according to a database managed by an
agency under the U.S. National Institutes of Health.
[to top of second column]
|
Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen
in front of a displayed Biontech logo in this illustration taken
December 11, 2021. REUTERS/Dado Ruvic/Illustration
BioNTech and its Chinese partner,
Shanghai Fosun Pharmaceutical Group, were not immediately available
to comment.
(Reporting by Roxanne Liu in Beijing and Patricia Weiss in
Frankfurt; Editing by Clarence Fernandez)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |